Prenetics Acquires ACT Genomics
Summary
With the acquisition, Prenetics will expand its footprint in the cancer genomics space. The company expects ACT to contribute revenues of approximately US$25-30 million in 2023. Led by CEO Dr. Hua Chien Chen, ACT Genomics is an innovation-driven cancer solution provider with offices in Taipei, Hong Kong, Singapore, Tokyo, Bangkok and UK. With its Sequencing (NGS) technology, CAP-accredited laboratories, experienced bioinformatics team, and proprietary AI algorithms, the company provides cancer treatment planning, immunotherapy evaluation, cancer relapse & drug resistance monitoring, as well as cancer risk assessment services to medical professionals. The company has operations across nine locations, including United Kingdom, Hong Kong, India, South Africa, and Southeast Asia.